John Valliere-Douglass

Seagen Inc.

John Valliere-Douglass is biotechnology professional with 25 years of industry experience in mass spectrometry and biotherapeutic protein characterization. He has authored over 30 publications on various aspects of mAb and antibody-drug conjugate (ADC) characterization and is a former co-chair for the CASSS mass spectrometry symposium. John is currently employed as a Scientific Leader at Seagen Inc. where he leads a core mass spectrometry group in the Process Development organization and serves as a cross-discipline key opinion leader that champions and establishes goals that position Seagen as a continued global leader in the development of oncology therapeutics.